Obesity appears to increase the risk of developing polycystic ovary syndrome (PCOS), according to a study presented at ENDO 2023. An estimated 7% to 10% of all reproductive-aged women globally have PCOS. Women with PCOS have a hormonal imbalance and metabolism problems that may affect their overall health, appearance, and fertility. PCOS is associated with health...
Released in May, “Endocrine Health and Health Care Disparities in the Pediatric and Sexual and Gender Minority Populations: An Endocrine Society Scientific Statement,” was a featured session on the last day of ENDO 2023. Endocrine News spoke to some of the authors about these updated treatment protocols. Year after year, the Endocrine Society’s Annual Conferences...
In otherwise healthy short children, quality of life and self-esteem are associated with coping skills and how supported they feel, not the degree of their short stature, according to a study recently published in The Journal of Pediatrics. Researchers led by Adda Grimberg, MD, a pediatric endocrinologist and Scientific Director of the Growth Center at Children’s...
Deletion of androgen receptors (ARs) in leptin receptor (LepRb) neurons improves estrous cycles, providing a possible therapeutic target for the symptoms of polycystic ovarian syndrome (PCOS), according to a mouse study recently published in Endocrinology. Researchers led by Carol F. Elias, PhD, of the University of Michigan Medical School’s Department of Molecular and Integrative Physiology,...
Pediatric growth hormone deficiency treatments could soon be painless. Fernando Cassorla, MD, is traveling from Chile to Chicago to present research at ENDO 2023 that could potentially change the way pediatric hormone treatments are administered. If a pill could replace painful injections, patients and caregivers alike can finally wipe away their tears. A convenient, well...
In a new Scientific Statement released today, the Endocrine Society identifies areas for future endocrine research to reduce health disparities in pediatric and sexual and gender minoritized populations. This Scientific Statement expands the Society’s 2012 statement by focusing on endocrine disease disparities in the pediatric and sexual and gender minoritized populations. These include pediatric and...
The U.S. Food and Drug Administration (FDA) last month approved a new indication for somapacitan-beco injection 5 mg, 10 mg, or 15 mg for the treatment of children aged 2.5 years and older who have growth failure due to inadequate secretion of endogenous growth hormone. Novo Nordisk is marketing the treatment as Sogroya® The FDA approval...
Therapeutic program targets a novel mechanism of melatonin receptor action outside of the CNS Celmatix Inc. today announced its latest drug program that targets melatonin receptors outside of the central nervous system (CNS). The company hopes the therapeutic drug will address a critical gap in the market for effective first-line treatments for a range of...
Pediatric growth hormone deficiency treatments could soon be painless. Fernando Cassorla, MD, is traveling from Chile to Chicago to present research at ENDO 2023 that could potentially change the way pediatric hormone treatments are administered. If a pill could replace painful injections, patients and caregivers alike can finally wipe away their tears. A convenient, well...
